In recent years, Wockhardt’s growth has been propelled by consistent expansion in the global generics market. Wockhardt has an aggressive programme targeting three strategic platforms for launching generic products in the advanced markets.

These are

Injectables, Blockbuster molecules going off patent, Value-added generics.

Wockhardt has filed abbreviated new drug applications (ANDAs) with the US FDA. More than 50 products are in various stages of development. The company now has 23 products being sold in the US under own banner.